/
CAD/PAD in Primary Care CV Risk in Stable Outpatients CAD/PAD in Primary Care CV Risk in Stable Outpatients

CAD/PAD in Primary Care CV Risk in Stable Outpatients - PowerPoint Presentation

stefany-barnette
stefany-barnette . @stefany-barnette
Follow
343 views
Uploaded On 2019-02-14

CAD/PAD in Primary Care CV Risk in Stable Outpatients - PPT Presentation

Stratified by Baseline CV Risk Category Aspirin for Secondary Prevention of CV Disease Anticoagulant Therapy in CAD Warfarin WARIS2 ATLAS ACS 2 TIMI 51 Rivaroxaban vs Placebo After ACS COMPASS ID: 751807

pad compass cad rivaroxaban compass pad rivaroxaban cad death therapy primary risk concerns managing outcomes stroke trial tolerability acs

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "CAD/PAD in Primary Care CV Risk in Stabl..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

CAD/PAD in Primary CareSlide2
Slide3

CV Risk in Stable OutpatientsStratified by Baseline CV Risk CategorySlide4

Aspirin for Secondary Prevention of CV DiseaseSlide5

Anticoagulant Therapy in CAD

Warfarin -- WARIS-2Slide6

ATLAS ACS 2 -- TIMI 51

Rivaroxaban vs Placebo After ACSSlide7

COMPASSTrial DesignSlide8

COMPASSPrimary Efficacy Outcome -- CV Death/MI/StrokeSlide9

COMPASSCumulative Risk of CV Death/Stroke/MISlide10

COMPASSBleeding OutcomesSlide11

COMPASSCV Death and All-Cause DeathSlide12

COMPASS: CAD and PAD CohortsSlide13

COMPASS PAD CohortPeripheral Limb OutcomesSlide14

Potential Tolerability Concerns With Adding Rivaroxaban TherapySlide15

Managing Tolerability ConcernsSlide16

Strategies to Improve Persistence and Adherence to Rivaroxaban Therapy Slide17

Correct Dose of RivaroxabanSlide18

VOYAGER PADSlide19

PADScreening Recommendations Slide20

RivaroxabanFDA Approval: October 15, 2018Slide21

External Applicability of the COMPASS Trial

REACH RegistrySlide22

Managing Patients with Stable CAD/PAD in Primary CareSlide23

SummarySlide24